Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
Abstract
:1. Introduction
2. Clinical Characteristics and Pathogenesis of Lung Fibrosis
2.1. Definition and Diagnosis
2.2. Risk Factors and Genetics
2.3. Pathogenesis
3. Progressive Fibrosing Interstitial Lung Disease
4. Treatment of Progressive Fibrosing Interstitial Lung Disease
5. Adoption of New Drugs in Clinical Practice and Treatment Optimization
6. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Distler, J.H.W.; Gyorfi, A.H.; Ramanujam, M.; Whitfield, M.L.; Konigshoff, M.; Lafyatis, R. Shared and distinct mechanisms of fibrosis. Nat. Rev. Rheumatol. 2019, 15, 705–730. [Google Scholar] [CrossRef]
- Rockey, D.C.; Bell, P.D.; Hill, J.A. Fibrosis—A common pathway to organ injury and failure. N. Engl. J. Med. 2015, 372, 1138–1149. [Google Scholar] [CrossRef]
- Cottin, V.; Hirani, N.A.; Hotchkin, D.L.; Nambiar, A.M.; Ogura, T.; Otaola, M.; Skowasch, D.; Park, J.S.; Poonyagariyagorn, H.K.; Wuyts, W.; et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 2018, 27, 180076. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wijsenbeek, M.; Cottin, V. Spectrum of Fibrotic Lung Diseases. N. Engl. J. Med. 2020, 383, 958–968. [Google Scholar] [CrossRef] [PubMed]
- Ryerson, C.J.; Kolb, M. The increasing mortality of idiopathic pulmonary fibrosis: Fact or fallacy? Eur. Respir. J. 2018, 51, 1702420. [Google Scholar] [CrossRef] [PubMed]
- Olson, A.; Hartmann, N.; Patnaik, P.; Wallace, L.; Schlenker-Herceg, R.; Nasser, M.; Richeldi, L.; Hoffmann-Vold, A.M.; Cottin, V. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Adv. Ther. 2021, 38, 854–867. [Google Scholar] [CrossRef] [PubMed]
- Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu, G.; Anstrom, K.J.; King, T.E., Jr.; Lasky, J.A.; Martinez, F.J. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012, 366, 1968–1977. [Google Scholar] [CrossRef]
- De Sadeleer, L.J.; Goos, T.; Yserbyt, J.; Wuyts, W.A. Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage. J. Clin. Med. 2020, 9, 1722. [Google Scholar] [CrossRef]
- King, T.E., Jr.; Bradford, W.Z.; Castro-Bernardini, S.; Fagan, E.A.; Glaspole, I.; Glassberg, M.K.; Gorina, E.; Hopkins, P.M.; Kardatzke, D.; Lancaster, L.; et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2083–2092. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Noble, P.W.; Albera, C.; Bradford, W.Z.; Costabel, U.; Glassberg, M.K.; Kardatzke, D.; King, T.E., Jr.; Lancaster, L.; Sahn, S.A.; Szwarcberg, J.; et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011, 377, 1760–1769. [Google Scholar] [CrossRef]
- Richeldi, L.; du Bois, R.M.; Raghu, G.; Azuma, A.; Brown, K.K.; Costabel, U.; Cottin, V.; Flaherty, K.R.; Hansell, D.M.; Inoue, Y.; et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2071–2082. [Google Scholar] [CrossRef] [Green Version]
- Flaherty, K.R.; Wells, A.U.; Cottin, V.; Devaraj, A.; Walsh, S.L.F.; Inoue, Y.; Richeldi, L.; Kolb, M.; Tetzlaff, K.; Stowasser, S.; et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N. Engl. J. Med. 2019, 381, 1718–1727. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Distler, O.; Highland, K.B.; Gahlemann, M.; Azuma, A.; Fischer, A.; Mayes, M.D.; Raghu, G.; Sauter, W.; Girard, M.; Alves, M.; et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N. Engl. J. Med. 2019, 380, 2518–2528. [Google Scholar] [CrossRef]
- O’Callaghan, M.; Bonella, F.; McCarthy, C. Unclassifiable, or simply unclassified interstitial lung disease? Curr. Opin. Pulm. Med. 2021, 27, 405–413. [Google Scholar] [CrossRef]
- Maher, T.M.; Corte, T.J.; Fischer, A.; Kreuter, M.; Lederer, D.J.; Molina-Molina, M.; Axmann, J.; Kirchgaessler, K.U.; Samara, K.; Gilberg, F.; et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020, 8, 147–157. [Google Scholar] [CrossRef]
- European Medicines Agency. Ofev. Nintedanib. EPAR—Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/ofev (accessed on 29 June 2021).
- U.S. Food and Drug Administration. OFEV® (Nintedanib Capsules), for Oral Use. Prescribing Information. Available online: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ofev/ofev.pdf (accessed on 30 June 2021).
- European Medicines Agency. Esbriet. Pirfenidone. EPAR—Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet (accessed on 29 June 2021).
- U.S. Food and Drug Administration. ESBRIET® (Pirfenidone) Capsules and Film-Coated Tablets, for Oral Use. Prescribing Information. Available online: https://www.gene.com/download/pdf/esbriet_prescribing.pdf (accessed on 30 June 2021).
- Raghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.F.; Flaherty, K.R.; Lasky, J.A.; et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011, 183, 788–824. [Google Scholar] [CrossRef]
- Raghu, G.; Remy-Jardin, M.; Myers, J.L.; Richeldi, L.; Ryerson, C.J.; Lederer, D.J.; Behr, J.; Cottin, V.; Danoff, S.K.; Morell, F.; et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2018, 198, e44–e68. [Google Scholar] [CrossRef] [PubMed]
- Lynch, D.A.; Sverzellati, N.; Travis, W.D.; Brown, K.K.; Colby, T.V.; Galvin, J.R.; Goldin, J.G.; Hansell, D.M.; Inoue, Y.; Johkoh, T.; et al. Diagnostic criteria for idiopathic pulmonary fibrosis: A Fleischner Society White Paper. Lancet Respir. Med. 2018, 6, 138–153. [Google Scholar] [CrossRef]
- Funke-Chambour, M.; Albera, C.; Bendstrup, E.; Costabel, U.; Grutters, J.C.; Harari, S.; Johannson, K.A.; Kreuter, M.; Strambu, I.; Vancheri, C.; et al. Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: Results of a Delphi survey. Eur. Respir. J. 2021, 57, 2004219. [Google Scholar] [CrossRef] [PubMed]
- Puglisi, S.; Torrisi, S.E.; Giuliano, R.; Vindigni, V.; Vancheri, C. What We Know About the Pathogenesis of Idiopathic Pulmonary Fibrosis. Semin. Respir. Crit. Care Med. 2016, 37, 358–367. [Google Scholar] [CrossRef] [PubMed]
- Newton, C.A.; Molyneaux, P.L.; Oldham, J.M. Clinical Genetics in Interstitial Lung Disease. Front. Med. 2018, 5, 116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Armanios, M.Y.; Chen, J.J.; Cogan, J.D.; Alder, J.K.; Ingersoll, R.G.; Markin, C.; Lawson, W.E.; Xie, M.; Vulto, I.; Phillips, J.A., 3rd; et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2007, 356, 1317–1326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsakiri, K.D.; Cronkhite, J.T.; Kuan, P.J.; Xing, C.; Raghu, G.; Weissler, J.C.; Rosenblatt, R.L.; Shay, J.W.; Garcia, C.K. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl. Acad. Sci. USA 2007, 104, 7552–7557. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seibold, M.A.; Wise, A.L.; Speer, M.C.; Steele, M.P.; Brown, K.K.; Loyd, J.E.; Fingerlin, T.E.; Zhang, W.; Gudmundsson, G.; Groshong, S.D.; et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 2011, 364, 1503–1512. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wells, A.U.; Brown, K.K.; Flaherty, K.R.; Kolb, M.; Thannickal, V.J.; Group, I.P.F.C.W. What’s in a name? That which we call IPF, by any other name would act the same. Eur. Respir. J. 2018, 51, 1800692. [Google Scholar] [CrossRef] [Green Version]
- Selman, M.; King, T.E.; Pardo, A.; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001, 134, 136–151. [Google Scholar] [CrossRef]
- Phan, S.H. Biology of fibroblasts and myofibroblasts. Proc. Am. Thorac. Soc. 2008, 5, 334–337. [Google Scholar] [CrossRef]
- Walsh, S.L.F.; Devaraj, A.; Enghelmayer, J.I.; Kishi, K.; Silva, R.S.; Patel, N.; Rossman, M.D.; Valenzuela, C.; Vancheri, C. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 2018, 27, 180073. [Google Scholar] [CrossRef]
- Brown, K.K.; Martinez, F.J.; Walsh, S.L.F.; Thannickal, V.J.; Prasse, A.; Schlenker-Herceg, R.; Goeldner, R.G.; Clerisme-Beaty, E.; Tetzlaff, K.; Cottin, V.; et al. The natural history of progressive fibrosing interstitial lung diseases. Eur. Respir. J. 2020, 55, 2000085. [Google Scholar] [CrossRef]
- Nasser, M.; Larrieu, S.; Si-Mohamed, S.; Ahmad, K.; Boussel, L.; Brevet, M.; Chalabreysse, L.; Fabre, C.; Marque, S.; Revel, D.; et al. Progressive fibrosing interstitial lung disease: A clinical cohort (the PROGRESS study). Eur. Respir. J. 2021, 57, 2002718. [Google Scholar] [CrossRef]
- Wijsenbeek, M.; Kreuter, M.; Olson, A.; Fischer, A.; Bendstrup, E.; Wells, C.D.; Denton, C.P.; Mounir, B.; Zouad-Lejour, L.; Quaresma, M.; et al. Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management. Curr. Med. Res. Opin. 2019, 35, 2015–2024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Faverio, P.; Piluso, M.; De Giacomi, F.; Della Zoppa, M.; Cassandro, R.; Harari, S.; Luppi, F.; Pesci, A. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers. Respiration 2020, 99, 838–845. [Google Scholar] [CrossRef] [PubMed]
- Walsh, S.L.F.; Lederer, D.J.; Ryerson, C.J.; Kolb, M.; Maher, T.M.; Nusser, R.; Poletti, V.; Richeldi, L.; Vancheri, C.; Wilsher, M.L.; et al. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2019, 200, 1146–1153. [Google Scholar] [CrossRef]
- Maher, T.M.; Brown, K.K.; Kreuter, M.; Devaraj, A.; Walsh, S.L.F.; Lancaster, L.H.; Belloli, E.A.; Padilla, M.; Behr, J.; Goeldner, R.G.; et al. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. Eur. Respir. J. 2021, 2004587. [Google Scholar] [CrossRef]
- Khine, N.; Mudawi, D.; Rivera-Ortega, P.; Leonard, C.; Chaudhuri, N.; Margaritopoulos, G.A. Rapidly non-ipf progressive fibrosing interstitial lung disease: A phenotype with an ipf-like behavior. Sarcoidosis Vasc. Diffus. Lung Dis. 2020, 37, 231–233. [Google Scholar] [CrossRef]
- George, P.M.; Spagnolo, P.; Kreuter, M.; Altinisik, G.; Bonifazi, M.; Martinez, F.J.; Molyneaux, P.L.; Renzoni, E.A.; Richeldi, L.; Tomassetti, S.; et al. Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir. Med. 2020, 8, 925–934. [Google Scholar] [CrossRef]
- Torres, P.; Rabahi, M.F.; Moreira, M.; Escuissato, D.L.; Meirelles, G.S.P.; Marchiori, E. Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases. J. Bras. Pneumol. 2021, 47, e20200096. [Google Scholar] [CrossRef] [PubMed]
- Devaraj, A.; Milanese, G.; Sverzellati, N. Thoracic computed tomography in the progressive fibrotic phenotype. Curr. Opin. Pulm. Med. 2021, 27, 350–354. [Google Scholar] [CrossRef]
- Hyldgaard, C. A cohort study of Danish patients with interstitial lung diseases: Burden, severity, treatment and survival. Dan. Med. J. 2015, 62, B5069. [Google Scholar]
- Horimasu, Y.; Ohshimo, S.; Yamaguchi, K.; Sakamoto, S.; Masuda, T.; Nakashima, T.; Miyamoto, S.; Iwamoto, H.; Fujitaka, K.; Hamada, H.; et al. A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia: A proof-of-concept study. Medicine 2021, 100, e24738. [Google Scholar] [CrossRef]
- Ravaglia, C.; Nicholson, A.G. Biopsy in interstitial lung disease: Specific diagnosis and the identification of the progressive fibrotic phenotype. Curr. Opin. Pulm. Med. 2021, 27, 355–362. [Google Scholar] [CrossRef]
- Juge, P.A.; Lee, J.S.; Ebstein, E.; Furukawa, H.; Dobrinskikh, E.; Gazal, S.; Kannengiesser, C.; Ottaviani, S.; Oka, S.; Tohma, S.; et al. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N. Engl. J. Med. 2018, 379, 2209–2219. [Google Scholar] [CrossRef]
- Ley, B.; Newton, C.A.; Arnould, I.; Elicker, B.M.; Henry, T.S.; Vittinghoff, E.; Golden, J.A.; Jones, K.D.; Batra, K.; Torrealba, J.; et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: An observational cohort-control study. Lancet Respir. Med. 2017, 5, 639–647. [Google Scholar] [CrossRef]
- Juge, P.A.; Borie, R.; Kannengiesser, C.; Gazal, S.; Revy, P.; Wemeau-Stervinou, L.; Debray, M.P.; Ottaviani, S.; Marchand-Adam, S.; Nathan, N.; et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur. Respir. J. 2017, 49, 1602314. [Google Scholar] [CrossRef] [PubMed]
- Mak, A.C.; Tang, P.L.; Cleveland, C.; Smith, M.H.; Kari Connolly, M.; Katsumoto, T.R.; Wolters, P.J.; Kwok, P.Y.; Criswell, L.A. Brief Report: Whole-Exome Sequencing for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2016, 68, 2257–2262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kolb, M.; Vasakova, M. The natural history of progressive fibrosing interstitial lung diseases. Respir. Res. 2019, 20, 57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Raghu, G.; Rochwerg, B.; Zhang, Y.; Garcia, C.A.; Azuma, A.; Behr, J.; Brozek, J.L.; Collard, H.R.; Cunningham, W.; Homma, S.; et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015, 192, e3–e19. [Google Scholar] [CrossRef]
- Wells, A.U.; Flaherty, K.R.; Brown, K.K.; Inoue, Y.; Devaraj, A.; Richeldi, L.; Moua, T.; Crestani, B.; Wuyts, W.A.; Stowasser, S.; et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020, 8, 453–460. [Google Scholar] [CrossRef]
- Richeldi, L.; Varone, F.; Bergna, M.; de Andrade, J.; Falk, J.; Hallowell, R.; Jouneau, S.; Kondoh, Y.; Morrow, L.; Randerath, W.; et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: A review of the current evidence. Eur. Respir. Rev. 2018, 27, 180074. [Google Scholar] [CrossRef] [Green Version]
- Richeldi, L.; Fernandez Perez, E.R.; Costabel, U.; Albera, C.; Lederer, D.J.; Flaherty, K.R.; Ettinger, N.; Perez, R.; Scholand, M.B.; Goldin, J.; et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 2020, 8, 25–33. [Google Scholar] [CrossRef]
- D’Alessandro, M.; De Vita, E.; Bergantini, L.; Mazzei, M.A.; di Valvasone, S.; Bonizzoli, M.; Peris, A.; Sestini, P.; Bargagli, E.; Bennett, D. Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases. Respir. Physiol. Neurobiol. 2020, 282, 103546. [Google Scholar] [CrossRef]
- Hirani, N.; MacKinnon, A.C.; Nicol, L.; Ford, P.; Schambye, H.; Pedersen, A.; Nilsson, U.J.; Leffler, H.; Sethi, T.; Tantawi, S.; et al. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2021, 57, 2002559. [Google Scholar] [CrossRef] [PubMed]
- Lamas, D.J.; Kawut, S.M.; Bagiella, E.; Philip, N.; Arcasoy, S.M.; Lederer, D.J. Delayed access and survival in idiopathic pulmonary fibrosis: A cohort study. Am. J. Respir. Crit. Care Med. 2011, 184, 842–847. [Google Scholar] [CrossRef] [PubMed]
- Cottin, V.; Richeldi, L.; Rosas, I.; Otaola, M.; Song, J.W.; Tomassetti, S.; Wijsenbeek, M.; Schmitz, M.; Coeck, C.; Stowasser, S.; et al. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir. Res. 2021, 22, 84. [Google Scholar] [CrossRef] [PubMed]
- Highland, K.B.; Distler, O.; Kuwana, M.; Allanore, Y.; Assassi, S.; Azuma, A.; Bourdin, A.; Denton, C.P.; Distler, J.H.W.; Hoffmann-Vold, A.M.; et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: A subgroup analysis of the SENSCIS trial. Lancet Respir. Med. 2021, 9, 96–106. [Google Scholar] [CrossRef]
- Shochet, G.E.; Pomerantz, A.; Shitrit, D.; Bardenstein-Wald, B.; Ask, K.; Surber, M.; Rabinowicz, N.; Levy, Y.; Benchetrit, S.; Edelstein, E.; et al. Galectin-3 levels are elevated following nintedanib treatment. Ther. Adv. Chronic Dis. 2020, 11, 2040622320968412. [Google Scholar] [CrossRef] [PubMed]
- Kolb, M.R.; Flaherty, K.R. The justification for the progressive fibrotic phenotype. Curr. Opin. Pulm. Med. 2021, 27, 363–367. [Google Scholar] [CrossRef]
- Wells, A.U.; Brown, K.K.; Cottin, V. The progressive fibrotic phenotype in current clinical practice. Curr. Opin. Pulm. Med. 2021, 27, 368–373. [Google Scholar] [CrossRef]
Definitions |
---|
|
|
|
|
|
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Albera, C.; Verri, G.; Sciarrone, F.; Sitia, E.; Mangiapia, M.; Solidoro, P. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective. Biomedicines 2021, 9, 1237. https://doi.org/10.3390/biomedicines9091237
Albera C, Verri G, Sciarrone F, Sitia E, Mangiapia M, Solidoro P. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective. Biomedicines. 2021; 9(9):1237. https://doi.org/10.3390/biomedicines9091237
Chicago/Turabian StyleAlbera, Carlo, Giulia Verri, Federico Sciarrone, Elena Sitia, Mauro Mangiapia, and Paolo Solidoro. 2021. "Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective" Biomedicines 9, no. 9: 1237. https://doi.org/10.3390/biomedicines9091237